Panaxia Labs Israel Ltd. (“Panaxia Israel”), (TASE: PNAX), a global pharma company, specializes in developing, manufacturing, and marketing advanced medical cannabis products in pharmaceutical quality and its partner, Neuraxpharm, Europe’s leading Pharma Company focused on the treatment of Central Nervous System (CNS) disorders, announced today expanding their strategic collaboration into the Polish market. The companies signed an exclusive agreement to the manufacture, commercialization, and distribution of Panaxia’s advanced medical cannabis-based products in Poland, a large market with significant growth potential in European and global standards, after a former successful collaboration in Germany and France. The commercial collaboration between both companies will be executed in a similar model to their cooperation in Germany: Panaxia will be responsible for the manufacturing of the products, developed under strict clinical standards. The products will include premium oils, and inhaled extracts, complying with European standards (EU-GMP). Neuraxpharm will be in charge of the branding, distribution, and marketing of the products to doctors, patients, and pharmacies in Poland.

Sean Hocking, Cannabis Law Report, 08/19/2021 21:35:00

Open article: